Gilead Sciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of twenty one analysts for the quarter was for earnings of $1.96 per share. Wall Street expected results to range from $1.86 to $2.05 per share.

• Revenue rose 1.8% to $7.08 billion from a year ago; analysts expected $6.96 billion.

• Gilead Sciences Inc's reported EPS for the quarter was $1.56​.

• The company reported quarterly net income of $1.96 billion.

• Gilead Sciences Inc shares had fallen by 0.5% this quarter and gained 19.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Gilead Sciences Inc is $120.00, about 8.1% above its last closing price of $110.28

This summary was machine generated from LSEG data August 8 at 03:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)